Gene single nucleotide polymorphism accumulation improves survival in advanced head and neck cancer patients treated with weekly paclitaxel

Laryngoscope

Volumn 119, Issue 8, 2009, Pages 1484-1490

  Grau, Juan J ^a   Caballero, Miguel ^a   Campayo, Marc ^a   Jansa, Sonia ^a   Vargas, Mauricio ^a   Alós, Llucia ^a   Monzo, Mariano ^a  

^a UNIVERSITY OF BARCELONA   (Spain)

Author keywords

Chemotherapy; Head and neck cancer

Indexed keywords

CYTOCHROME P450 2C8; DEXAMETHASONE; DIPHENHYDRAMINE; EXCISION REPAIR CROSS COMPLEMENTING PROTEIN 1; GLUTATHIONE TRANSFERASE P1; GLUTATHIONE TRANSFERASE T1; MULTIDRUG RESISTANCE PROTEIN; MULTIDRUG RESISTANCE PROTEIN 1-57; MULTIDRUG RESISTANCE PROTEIN 1-62; PACLITAXEL; RANITIDINE; UNCLASSIFIED DRUG;

ADULT; ADVANCED CANCER; AGED; ALOPECIA; ANEMIA; ARTICLE; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER RADIOTHERAPY; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL EVALUATION; CONTROLLED STUDY; DESQUAMATION; DIARRHEA; DISEASE SEVERITY; DRUG EFFICACY; DRUG ERUPTION; DRUG METABOLISM; DRUG SAFETY; DRUG WITHDRAWAL; FATIGUE; FEMALE; GENE; GENE EXPRESSION; HEAD AND NECK CANCER; HUMAN; LEUKOPENIA; MALE; NAUSEA; OVERALL SURVIVAL; PARESTHESIA; PHARYNGITIS; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; SINGLE NUCLEOTIDE POLYMORPHISM; STOMATITIS; THROMBOCYTOPENIA; THROMBOPHLEBITIS; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE; WILD TYPE;

AGED; AGED, 80 AND OVER; ANALYSIS OF VARIANCE; CONFIDENCE INTERVALS; DISEASE-FREE SURVIVAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; ENDONUCLEASES; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENETIC MARKERS; HEAD AND NECK NEOPLASMS; HUMANS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASM INVASIVENESS; NEOPLASM STAGING; NUCLEAR PROTEINS; PACLITAXEL; PALLIATIVE CARE; POLYMORPHISM, SINGLE NUCLEOTIDE; PROBABILITY; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 68849110774     PISSN: 0023852X     EISSN: None     Source Type: Journal    
DOI: 10.1002/lary.20254     Document Type: Article

References (23)

1. Marsh S. Pharmacogenomics. Ann Oncol 2007;18(suppl 9): ix24-ix28.
2. Marsh S, McLeod HL. Cancer pharmacogenetics. Br J Cancer 2004;90:8-11.
3. Brotherton TW, Ritch P, Ervin T, et al. Phase II multicenter trial of paclitaxel weekly one hour infusion in previously treated advanced head/neck cancer. Proc Am Soc Clin Oncol 2001:20. Abstract 921.
4. Nakajima M, Fujiki Y, Kyo S, et al. Pharmacokinetics of paclitaxel in ovarian cancer patients and genetic polymorphisms of CYP2C8, CYP3A4 and MDR1. Pharmacogenomics 2005;45:674-682.
5. Medeiros R, Pereira D, Afonso N, et al. Platinum/paclitaxel-based chemotherapy in advanced ovarian carcinoma: glutathione S-transferase genetic polymorphisms as predictive biomarkers of disease outcome. Int J Clin Oncol 2003;8:156-161.
6. Arai T, Miyoshi Y, Kim SJ, et al. Association of GSTP1 expression with resistance to docetaxel and paclitaxel in human breast cancers. Eur J Surg Oncol 2008;34: 734-738.
7. Obata H, Yahata T, Ouan J, Sekine M, Tanaka K. Association between single nucleotide polymorphisms of drug- associated genes and response to chemotherapy in advanced ovarian cancer. Anticancer Res 2006;26: 2227-2232.
8. Darcy KM, Tian CQ, Reed E, et al. A gynecologic oncology group study of platinum-DNA adducts and excision repair cross-complementation group 1 expression in optimal, stage III epithelial ovarian cancer treated with plat- inum-taxane chemotherapy. Cancer Res 2007;67: 4474-4481.
9. Crouthamel MH, Wu D, Yang Z, Ho RJ. A novel MDR1 G1199T variant alters drug resistance and efflux transport activity of P-glycoprotein in recombinant Hek cells. J Pharm Sci 2006;95:2767-2777.
10. Henningsson A, Marsh S, Loos WJ, et al. Association of CYP2C8, CYP3A4, CYP3A5, and ABCB1 polymorphisms with the pharmacokinetics of paclitaxel. Clin Cancer Res 2005;15:8097-8104.
11. Dai D, Zeldin DC, Blaisdell JA, et al. Polymorphisms in human CYP2C8 decrease metabolism of the anticancer drug paclitaxel and arachidonic acid. Pharmacogenetics 2001;11:597-607.
12. Green H, Soderkvist P, Rosenberg P, et al. mdr-1 single nu-cleotide polymorphisms ovarian cancer tissue: G2677T/A correlates with response to paclitaxel chemotherapy. Clin Cancer Res 2006;12:854-859.
13. Marsh S, King CR, McLeod HL, et al. ABCB1 2677G>T/A genotype and paclitaxel pharmacogenetics in ovarian cancer. Clin Cancer Res 2006;12:4127-4129.
14. Sissung TM, Mross K, Steinberg D, et al. Association of ABCB1 genotypes with paclitaxel-mediated peripheral neuropathy and neutropenia. Eur J Cancer 2006;42: 2893-2896.
15. 15.Bellmunt J, Paz-Ares L, Cuello M, et al. Gene expression of ERCC1 as a novel prognostic marker in advanced bladder cancer patients receiving cisplatin-based chemotherapy. Ann Oncol 2007;18:522-528.
16. Bewick MA, Conlon MS, Lafrenie RM. Polymorphisms in XRCC1, XRCC3, and CCND1 and survival after treatment for metastatic breast cancer. J Clin Oncol 2006;24: 5645-5651.
17. Monzo M, Brunet S, Urbano-Ispizua A, et al. Genomic polymorphisms provide prognostic information in intermediate-risk acute myeloblastic leukaemia. Blood 2006;107: 4871-4879.
18. Therase P, Arbuck SG, Eisenhauer AE, et al. New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 2000;92:205-216.
19. Marsh S, Paul J, King CR, Gifford G, McLeod HL, Brown R. Pharmacogenetic assessment of toxicity and outcome after platinum plus taxane chemotherapy in ovarian cancer: the Scottish Randomised Trial in Ovarian Cancer J Clin Oncol 2007;25:4528-4535.
20. Soyama A, Saito Y, Hanioka N, et al. Non-synonymous single nucleotide alterations found in the CYP2C8 gene result in reduced in vitro paclitaxel methabolism. Bio Pharm Bull 2001;24:1427-1430.
21. Soyama A, Saito Y, Komamura K, et al. Five novel single nucleotide polymorphisms in the CYP2C8 gene, one of which induces a frame-shift. Drug Metab Pharmacokinet 2002;17:374-377.
22. Lamba JK, Lin YS, Thummel K, et al. Common allelic variants of cytochrome P4503A4 and their prevalence in different populations. Pharmocogenetics 2002;12:121-132.
23. Hitt R, Irigoyen A, Nuñez J, et al. Phase II study of combination cetuximab and weekly paclitaxel in patients with metastatic/recurrent squamous cell carcinoma of head and neck: Spanish Head and Neck Cancer Group (TTCC). 2007 ASCO Annual Meeting Proceedings Part I. J Clin Oncol 2007;25(suppl):S302. Abstract 6012.